<DOC>
	<DOCNO>NCT01049282</DOCNO>
	<brief_summary>The study follow objective : Primary objective To evaluate safety profile adjuvanted TB subunit vaccine administer different antigen/adjuvant formulation 0 2 month Secondary objective To determine immunogenicity profile adjuvanted TB subunit vaccine administer different antigen/adjuvant formulation 0 2 month .</brief_summary>
	<brief_title>A Safety Immunogenicity Trial With Adjuvanted TB Subunit Vaccine ( Ag85B-ESAT-6 + IC31 )</brief_title>
	<detailed_description>Number trial subjects=48 Investigational product=Ag85B - ESAT-6 + IC31 Dosage Group 1 : TST negative , 50 µg antigen Group 2 : TST negative , 50 µg antigen + fix adjuvant Group 3 : BCG vaccinate , 50 µg antigen + fix adjuvant Group 4 : Latent TB , 50 µg antigen + fix adjuvant Dosage volume 0.5 ml Administration Intramuscularly deltoid muscle , alternate arm day 0 ( right ) day 56 ( leave ) .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male 18 40 year old TST negative group : TST negative QuantiFERONTB Gold In tube test BCG group : know BCGvaccinated &gt; 2 year ( scar , vaccination card ) , TST+ ( &gt; 6 document value &gt; 6 mm medical file past ) , active , chronic past TB disease confirm chest X ray , negative QuantiFERONTB Gold In Tube test negative 6day lymphocyte test . Infection group : latent TB , TST+ ( = &gt; 10 mm document = &gt; 10 mm positive medical file past ) , previously TB infect active disease confirm chest X ray , may receive chemoprophylaxis TB treatment/chemoprophylaxis within precede 2 year , positive QuantiFERONTB Gold In Tube test and/or positive 6day lymphocyte test . Healthy base medical examination/history inclusion Signed informed consent Prepared grant authorize person access medical record The volunteer likely comply instruction Confirmed active TB base clinical evaluation ( history , physical finding investigation ) Vaccinated vaccine 3 month first vaccination Administration immune modulate drug ( steroid , immunosuppressive drug immunoglobulin ) HBV , HCV HIV seropositive Participation clinical trial Known hypersensitivity vaccine component Laboratory parameter outside normal range consider clinically relevant</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>adjuvanted TB subunit vaccine</keyword>
</DOC>